Technology
Health
Medical

BioSig

$8.11
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.38 (-4.48%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BioSig and other stocks, options, ETFs, and crypto commission-free!

About

BioSig Technologies, Inc. operates as a medical device company. It engages in the development of proprietary biomedical signal processing technology platform to minimize noise and artifacts from cardiac recordings. Read More The company develops and designs the precise uninterrupted real-time evaluation of electrograms electrophysiology (EP) system which acquires, processes, and displays electrocardiogram and electrograms required during EP studies and ablation procedures. BioSig Technologies was founded by Lora Mikolaitis, Budimir S. Drakulic and Kenneth L. Londoner on February 24, 2009 and is headquartered in Los Angeles, CA. BSGM is listed on the OTCQB market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).

Employees
20
Headquarters
Los Angeles, California
Founded
2009
Market Cap
162.28M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
71.52K
High Today
$8.46
Low Today
$7.70
Open Price
$8.46
Volume
185.61K
52 Week High
$9.97
52 Week Low
$3.50

Collections

Technology
Health
Medical
2018 IPO
US
North America

News

Seeking AlphaMay 7

BioSig Technologies Pivotal Moment

BioSig (BSGM) has just began commercializing their Pure EP system. The device acquires and provides clear real time data on cardiac signals to assist electrophysiologists in identifying areas of tissue that cause arrhythmia - a heart rhythm disturbance. What makes the Pure EP system a game changer is that it has the ability to pick up electrical currents that were previously not detectable, putting all competitors on notice that there's a new player in the arena. BioSig completed its first study of in-huma...

639
Associated PressMay 2

BioSig’s Manuscript Accepted to IEEE Engineering in Medicine and Biology Conference 2019

Santa Monica, CA, May 02, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address unmet needs for the electrophysiology (EP) marketplace, today announced that the manuscript entitled “Evaluation of Real Time Catheter Tissue Contact using Unipolar Intracardiac Signal Morphology” has been accepted to the 41st International Engineering in Medicine and Biology Conference (EMBC), to be held in B...

153
Associated PressApr 30

BioSig To Participate at Heart Rhythm Society’s Scientific Sessions 2019

Santa Monica, CA, April 30, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address unmet needs for the electrophysiology (EP) marketplace, today announced that the Company will be exhibiting at the Heart Rhythm Society’s 40th Annual Scientific Sessions on May 8-11, 2019 at Moscone Center in San Francisco, CA. During the event BioSig will be presenting at booth 2056 in the South Hall of Mo...

68

Earnings

Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 26
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.